Oral Mucositis Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Oral Mucositis Therapeutics is Forecast to show High growth Until 2017, The report is an essential source of information and analysis on the global oral mucositis market. GlobalData estimated the oral mucositis therapeutics market was valued at $813.2m in 2010. Further the oral mucositis therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 5.2% from $813.2m in 2010 to $1.1 billion until 2017. The growth would be primarily due to the increase in cancer patients, availability of newer treatment options for cancer treatment and increase in awareness among patients about oral mucositis. Also uptake of recently launched products such as MuGard and expected launch of EASYEF, in the year 2014-2015 will further drive the market. In cancer patients undergoing chemotherapy and/or radiation treatment, one of the most commonly observed side effects related to these therapies is oral mucositis. Oral mucositis leads to development of painful lesions of the mouth, tongue and throat that leave many people unable to eat, speak or continue their life-saving treatments. Also, infections related to oral mucositis frequently require hospitalization and in some cases lead to death. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Oral-Mucositis-TherapeuticsPipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=In GlobalData found that the products currently available in the market for the treatment of oral mucositis have moderate efficacy and safety profiles and are able to provide symptomatic relief in some patients. The current treatment options are not able to prevent the progression of the disease and due to this; there is huge untapped potential in the market. Currently, the oral mucositis market is under-served and products such as Kepivance, Gelclair, MuGard and Caphosol are unable to satisfy the demand in the oral mucositis market. The oral mucositis therapeutics has a high level of unmet need as the market is not well-served with the current product options and there is scope for new entrants to capitalize on the market. The oral mucositis market consists of drugs that are approved for the symptomatic treatment of oral mucositis but none of the drugs are able to cure the disease. New products in this market must aim at getting market share by providing unique offerings which will target the untapped market. The untapped segment can be exploited through the availability of drugs that are effective, safe, and well-tolerated, and which can help in prevention of the disease. There is a need for new disease-modifying therapies which will stop the disease progression. GlobalData, the industry analysis specialist, has released its new report, “Oral Mucositis Therapeutics Pipeline Assessment and Market Forecasts to 2017�. The report is an essential source of information and analysis on the global oral mucositis market. The report identifies the key trends shaping and driving
the global oral mucositis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global oral mucositis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Oral-Mucositis-Therapeutics-PipelineAssessment-and-Market-Forecasts-to-2017&ReportType=In Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: Europe: Asia Pacific:
+1 646 395 5477 +44 207 753 4299 +44 1204 543 533 +91 40 6616 6782